Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996883 | 0.96 | MEN1 (0.38) | MEN1POLBKMT2ANPSR1 | |
| SCHEMBL1995141 | 0.91 | — | — | |
| SCHEMBL4045233 | 0.78 | MEN1 (0.36) | MEN1POLBKMT2A | |
| SCHEMBL8787564 | 0.77 | CTSL (0.39) | MEN1POLBKMT2A | |
| SCHEMBL9555416 | 0.76 | CTSL (0.38) | MEN1POLBKMT2A | |
| SCHEMBL4040561 | 0.74 | MEN1 (0.40) | MEN1POLBKMT2A | |
| SCHEMBL4047596 | 0.72 | MEN1 (0.43) | MEN1POLBKMT2A | |
| SCHEMBL15506875 | 0.71 | NPSR1 (0.34) | GLANPSR1 | |
| SCHEMBL29719452 | 0.69 | MEN1 (0.41) | MEN1POLBKMT2A | |
| SCHEMBL890111 | 0.68 | MAPT (0.35) | GLANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654807-B2 | Toll-like receptor 8 agonists | THE UNIVERSITY OF KANSAS (US) | 2020-05-19 | — | — | US | disclosed |
| US-10471139-B2 | Toll-like receptor agonists | THE UNIVERSITY OF KANSAS (US) | 2019-11-12 | — | — | US | disclosed |
| US-20160347715-A1 | Toll-Like Receptor 8 Agonists | THE UNIVERSITY OF KANSAS | 2016-12-01 | — | — | US | disclosed |
| US-20160229866-A1 | HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS INC. (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3046924-A1 | HEPATITIS C VIRUS INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2016-07-27 | — | — | EP | disclosed |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS | 2016-06-16 | — | — | US | disclosed |
| US-9187496-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2015095780-A1 | TOLL-LIKE RECEPTOR 8 AGONISTS | THE UNIVERSITY OF KANSAS (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015042375-A1 | HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015023958-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS (US) | 2015-02-19 | — | — | WO | disclosed |
| EP-2691093-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | IDENIX Pharmaceuticals, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-20130071352-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8362068-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| CN-102822175-A | 5, 5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS INC (US) | 2012-12-12 | — | — | CN | disclosed |
| EP-2513113-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2012135581-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2011075615-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071352-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | MEN1 4787/4885POLB 1923/4885KMT2A 4497/4885 |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR1, TLR7, TLR8 | MEN1 3805/4885POLB 1271/4885KMT2A 3217/4885 |
| US-10654807-B2 | Toll-like receptor 8 agonists | TLR8, TLR7, TLR1 | MEN1 4436/4885POLB 1652/4885KMT2A 2841/4885 |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | MEN1 4787/4885POLB 1923/4885KMT2A 4497/4885 |
| US-20160347715-A1 | Toll-Like Receptor 8 Agonists | TLR8, TLR7, TLR1 | MEN1 4436/4885POLB 1652/4885KMT2A 2841/4885 |
| US-10471139-B2 | Toll-like receptor agonists | TLR1, TLR7, TLR8 | MEN1 3805/4885POLB 1271/4885KMT2A 3217/4885 |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | HAVCR2, CYP3A5, CYP7A1 | MEN1 4546/4885POLB 1422/4885KMT2A 4174/4885 |
| US-20160229866-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, LIPC, LDHB | MEN1 4854/4885POLB 249/4885KMT2A 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.